mon-te-LOO-kast
REMS
Contraindicated in:
Use Cautiously in:
Derm: rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN)
EENT: epistaxis, otitis (children), rhinorrhea, sinusitis(children)
GI: ↑liver enzymes, abdominal pain, diarrhea(children), dyspepsia, nausea(children)
Neuro: aggression, agitation, anxiety, attention disturbance, depression, disorientation, dream abnormalities, fatigue, hallucinations, headache, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, sleep walking, stuttering, SUICIDAL THOUGHTS/BEHAVIORS, tics, tremor, weakness
Resp: cough
Misc: EOSINOPHILIC CONDITIONS (INCLUDING CHURG-STRAUSS SYNDROME), fever
Drug-drug:
Asthma
Exercise-Induced Bronchoconstriction
Allergic Rhinitis
Therapeutic Classification: allergy, cold and cough remedies, bronchodilators
Pharmacologic Classification: leukotriene antagonists
Absorption: Rapidly absorbed (63–73%) following oral administration.
Distribution: Minimally distributed to tissues.
Protein Binding: 99%.
Half-Life: 2.7–5.5 hr.
(improved symptoms of asthma)
| ROUTE | ONSET | PEAK‡ | DURATION |
|---|---|---|---|
| PO (swallow) | within 24 hr | 3–4 hr | 24 hr |
| PO (chew) | within 24 hr | 2–2.5 hr | 24 hr |
‡Plasma concentrations.
Encourage patient and family to be alert for emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania, worsening of depression, and suicidal ideation, especially during early antidepressant therapy. Assess symptoms on a day-to-day basis as changes may be abrupt. If these symptoms or rash occurs, notify health care provider.
NDC Code
